Dec 16 2024
Mind Medicine Inc., a clinical-stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that the first patient has been dosed in its Phase 3 Voyage study of MM120 ODT, a pharmaceutically optimized form of lysergide D-tartrate (LSD) for the treatment of GAD. Voyage is the first of two Phase 3 …
Dec 16 2024
Researchers from the University of Texas have conducted a study examining the impact of recreational psychedelics on bipolar disorder. Published online ahead of print by the US National Library of Medicine, the study, appearing in the upcoming issue of the Journal of Affective Disorders, examines how substances like psilocybin affect individuals with bipolar disorder (BD), …
Dec 13 2024
In a double-blind randomized controlled, acute cannabidiol administration reduced alcohol craving and cue-induced nucleus accumbens activation in individuals with alcohol use disorder. Published in the peer reviewed journal Molecular Psychiatry, researchers from the University of Heidelberg in Germany and Karolinska Institutet in Sweden have unveiled compelling evidence supporting cannabidiol (CBD) as a treatment for alcohol …
Dec 13 2024
Cannabidiolic acid (CBDA) encapsulated in alginate microcapsules shows extended antioxidant activity and reduced cytotoxicity, according to a newly published study. The study, titled Alginate-based microencapsulation as a strategy to improve the therapeutic potential of cannabidiolic acid, explores an innovative method for enhancing the bioavailability and effectiveness of CBDA, a compound found in marijuana. The research, …
Dec 12 2024
Lebanese cannabis oil extract (COE) has been found to provide significant protection against kidney fibrosis caused by folic acid (FA) in an animal model, according to a new study published in PLoS One. Researchers at Lebanese American University conducted in vitro and in vivo experiments to assess COE’s potential therapeutic effects on renal fibrosis, a …
Dec 12 2024
Researchers from London Metropolitan University, Regent’s University London, and Imperial College London found that cannabis suppositories and online mindful compassion interventions significantly improved sexual function and reduced pain for women recovering from gynaecological cancer. The study, published in the journal Medicina, highlights the profound effect such treatments have on female sexuality and the limited research …
Dec 10 2024
A new systematic review and network meta-analysis, published in the Journal of Psychopharmacology, explores the potential of psychedelics to alleviate existential distress in terminally ill patients. Conducted by researchers from the University of Modena and Reggio Emilia, the Italy Department of Mental Health and Drug Abuse, and the University Utrecht in the Netherlands, the study …
Dec 09 2024
Psychedelics like LSD and psilocybin may improve sexual function for months after use, according to a study conducted by the Centre for Psychedelic Research at Imperial College London. This research marks the first known scientific investigation into the long-term effects of psychedelics on sexual health. Participants in the study reported significant improvements across various aspects …
Dec 05 2024
A randomized clinical trial conducted by researchers from the University of Washington, Fred Hutchinson Cancer Center, and the Yale School of Medicine has found that psilocybin therapy significantly reduces symptoms of depression in clinicians who developed moderate to severe symptoms while providing frontline care during the COVID-19 pandemic. The aim of the study was to …
Dec 05 2024
Clinical data published in the peer reviewed journal Medical Cannabis and Cannabinoids shows that a transdermal cannabinoid oil significantly reduces pain associated with diabetic peripheral neuropathy (DPN). The study, conducted at Don Chan Hospital in Thailand, involved 100 participants in a 12-week randomized, double-blind, placebo-controlled trial. Researchers evaluated the effects of a novel THC:CBD:CBN transdermal …
